Photo: Lewis Geyer/Digital First Media/Boulder Daily Camera via Getty Images
A federal appeals court has upheld Amgen's patents tied to its blockbuster arthritis drug Enbrel, a decision that will block biosimilar competition until 2029. The FDA approved the first biosimilar to Enbrel in 2016.
The big picture: Amgen is heavily reliant on Enbrel, which brings in more than $5 billion in revenue per year. Now, the company — which has spent more money on stock buybacks than drug research since 2016 — has almost another decade of monopoly control over the drug, which has a net price of roughly $44,000 for a year of treatment.
Go deeper: Biosimilars are barely a thing